EUVIMEDObjevte EUVIMED
VergleichsstudieOpen access · CC BY 4.0

Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan

Anna Fleischer iD, Magdalena Roll, Jan H Frenking, Franziska Panther, Götz Gelbrich, Patrick-Pascal Strunz, Christine Riedhammer, Jessica Peter, Julia Mersi, Johannes Waldschmidt, Martin Kortüm, Hermann Einsele and 3 more

Cancer Medicine · 2025

DOI: 10.1002/cam4.71401 ↗

At a glance

Vergleichsstudie in Cancer Medicine, 2025. Written by Anna Fleischer and 14 co-authors. Institution: Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany. Major MEDLINE topics: Multiple Myeloma, Antibodies, Bispecific, Dysgeusia, Melphalan. Cited 12 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: IMS and Paula and Rodger Riney Foundation, Dietmar-Hopp-Foundation, Paula and Rodger Riney Foundation and the German Cancer Aid via the MSNZ programme.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Dysgeusia is a side effect of the anti‐GPRC5DxCD3 bispecific antibody talquetamab (TAL), but other myeloma treatments, such as high‐dose melphalan (MEL) with autologous stem cell transplantation (ASCT), are also known to alter taste perception in patients with multiple myeloma (MM). This study investigates the spectrum, prevalence and severity of dysgeusia in patients receiving TAL and MEL and compares the results with anti‐BCMA bispecifics as a control for T‐cell‐engaging therapies.

Methods

Gustatory and olfactory performance was assessed in 87 MM patients divided into three treatment groups: TAL ( n = 26), MEL/ASCT ( n = 35), and BCMA bispecifics ( n = 26). Evaluations included Taste Strips, Sniffin' Sticks Identification Test 16, and comprehensive questionnaires on taste perception, dietary issues, quality of life (QoL), mood, and treatment compliance.

Results

TAL‐treated patients exhibited severe taste impairment, with 96.2% reporting marked declines. Taste alterations were also observed in patients receiving MEL/ASCT and BCMA bispecifics, though these were less pronounced, affecting 62.9% and 30.8% of cases, respectively. Xerostomia incidence was highest in the TAL group. Patients considering discontinuation of TAL (30%) cited taste alterations as the primary reason. MEL was associated with higher incidences of nausea, vomiting, and appetite loss.

Conclusion

TAL‐associated taste disturbances have a major impact on patients and require further investigation and mitigation strategies. Enhanced patient support, proactive monitoring, and targeted interventions are critical to improving the well‐being and adherence of MM patients.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaAntibodies, BispecificDysgeusiaMelphalanHumansFemaleMaleMiddle AgedAgedQuality of LifeAdultB-Cell Maturation Antigen

Author keywords

gustatory dysfunctionimmunotherapyoral complicationsquality of lifetaste impairmenttreatment adherence

Substances

Antibodies, BispecificMelphalanB-Cell Maturation Antigentalquetamab

Authors and institutions

  • Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
  • Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Institute of Biometry and Epidemiology, University Hospital of Würzburg, Würzburg, Germany.

ORCID profiles: Anna Fleischer, Leo Rasche

Funding

  • IMS and Paula and Rodger Riney Foundation
  • Dietmar-Hopp-Foundation
  • Paula and Rodger Riney Foundation and the German Cancer Aid via the MSNZ programme
  • Else Kröner-Fresenius Foundation

Cite

APA

Fleischer, A., Roll, M., Frenking, J. H., Panther, F., Gelbrich, G., Strunz, P. P., Riedhammer, C., Peter, J., Mersi, J., Waldschmidt, J., Kortüm, M., Einsele, H., Raab, M. S., Maatouk, I., & Rasche, L. (2025). Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan. Cancer Medicine. https://doi.org/10.1002/cam4.71401

Vancouver

Fleischer A, Roll M, Frenking JH, Panther F, Gelbrich G, Strunz PP, et al. Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan. Cancer Medicine. 2025. doi:10.1002/cam4.71401

BibTeX
@article{Fleischer2025,
  author = {Fleischer, Anna and Roll, Magdalena and Frenking, Jan H and Panther, Franziska and Gelbrich, Götz and Strunz, Patrick-Pascal and Riedhammer, Christine and Peter, Jessica and Mersi, Julia and Waldschmidt, Johannes and Kortüm, Martin and Einsele, Hermann and Raab, Marc-S and Maatouk, Imad and Rasche, Leo},
  title = {Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71401}
}
Start for free →